These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2702093)

  • 1. Enhanced clearance of vancomycin by hemodialysis in a child.
    Schoumacher R; Chevalier RL; Gomez RA; Rogol AD; Cummings R; Spyker DA
    Pediatr Nephrol; 1989 Jan; 3(1):83-5. PubMed ID: 2702093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of slowly performed daytime hemodialysis (slow HD) on the pharmacokinetics of vancomycin in hemodynamically unstable patients with renal failure.
    Kihara M; Ikeda Y; Fujita H; Tamura K; Yabana M; Takagi N; Umemura S; Ishii M
    Blood Purif; 1996; 14(1):20-5. PubMed ID: 8718561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease.
    Touchette MA; Patel RV; Anandan JV; Dumler F; Zarowitz BJ
    Am J Kidney Dis; 1995 Sep; 26(3):469-74. PubMed ID: 7645555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile.
    Torras J; Cao C; Rivas MC; Cano M; Fernandez E; Montoliu J
    Clin Nephrol; 1991 Jul; 36(1):35-41. PubMed ID: 1889149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal of vancomycin by high-flux hemodialysis membranes.
    Quale JM; O'Halloran JJ; DeVincenzo N; Barth RH
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1424-6. PubMed ID: 1510437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics.
    Welage LS; Mason NA; Hoffman EJ; Odeh RM; Dombrouski J; Patel JA; Swartz RD
    J Am Soc Nephrol; 1995 Oct; 6(4):1284-90. PubMed ID: 8589298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin hemodialysis: Clearance differences between high-flux hemodialysis and on-line hemodiafiltration.
    Rodríguez N; Gómez M; Rico N; María Campistol J; Maduell F
    Artif Organs; 2019 Mar; 43(3):261-269. PubMed ID: 30302764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ofloxacin clearance during hemodialysis: a comparison of polysulfone and cellulose acetate hemodialyzers.
    Thalhammer F; Kletzmayr J; El Menyawi I; Kovarik J; Rosenkranz AR; Traunmüller F; Hörl WH; Burgmann H
    Am J Kidney Dis; 1998 Oct; 32(4):642-5. PubMed ID: 9774127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
    Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
    Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.
    Joy MS; Matzke GR; Frye RF; Palevsky PM
    Am J Kidney Dis; 1998 Jun; 31(6):1019-27. PubMed ID: 9631848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration.
    Mason NA; Neudeck BL; Welage LS; Patel JA; Swartz RD
    Clin Nephrol; 2003 Aug; 60(2):96-104. PubMed ID: 12940611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes.
    Zoer J; Schrander-van der Meer AM; van Dorp WT
    Pharm World Sci; 1997 Aug; 19(4):191-6. PubMed ID: 9297732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearance of vancomycin during high-efficiency hemodialysis.
    Klansuwan N; Ratanajamit C; Kasiwong S; Wangsiripaisan A
    J Med Assoc Thai; 2006 Jul; 89(7):986-91. PubMed ID: 16881431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dialysis membrane on intradialytic vancomycin administration.
    Scott MK; Macias WL; Kraus MA; Clark WR; Carfagna MA; Mueller BA
    Pharmacotherapy; 1997; 17(2):256-62. PubMed ID: 9085316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of vancomycin in patients with severely impaired renal function.
    Gonzalez-Martin G; Acuna V; Perez C; Labarca J; Guevara A; Tagle R
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):71-5. PubMed ID: 8929749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin therapy for serious staphylococcal infections in chronic hemodialysis patients.
    Bierman MH; Needham-Walker CA; Hammeke M; Egan JD
    J Dial; 1980; 4(4):179-84. PubMed ID: 7204716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of moxalactam in anuric children and during hemodialysis.
    Kaplan SL; Berry PL; Mason EO; Kramer WG
    Pediatr Pharmacol (New York); 1983; 3(1):29-36. PubMed ID: 6646877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Falsely elevated serum vancomycin concentrations in hemodialysis patients.
    Follin SL; Mueller BA; Scott MK; Carfagna MA; Kraus MA
    Am J Kidney Dis; 1996 Jan; 27(1):67-74. PubMed ID: 8546140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of vancomycin in patients on continuous arteriovenous hemodialysis.
    Reetze-Bonorden P; Böhler J; Kohler C; Schollmeyer P; Keller E
    Contrib Nephrol; 1991; 93():135-9. PubMed ID: 1802564
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration.
    De Bock V; Verbeelen D; Maes V; Sennesael J
    Nephrol Dial Transplant; 1989; 4(7):635-9. PubMed ID: 2510061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.